.avif)
Madrigal Pharmaceuticals Email Format
Pharmaceutical Manufacturing
・
501-1,000 employees
・
Conshohocken, PA, USA
Madrigal Pharmaceuticals is a biopharmaceutical company developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@madrigalpharma.com
Company Overview
Industry
Pharmaceutical Manufacturing
Founded
2016
Headquarters
Conshohocken, PA, USA
Revenue
$100M-$250M
FUNDING Stage
Public
Website
Key Executives
Bill Sibold (President and Chief Executive Officer), Mardi C. Dier (Executive Vice President, Chief Financial Officer), Mark Underwood (Executive Vice President, Business Planning & Operations)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals uses the firstinitiallast format on madrigalpharma.com, so Jane Smith would be jsmith@madrigalpharma.com.
What is Rezdiffra, and how does it fit into Madrigal Pharmaceuticals' treatment portfolio?
Rezdiffra (resmetirom) is Madrigal Pharmaceuticals' FDA-approved therapy for adults with MASH and moderate to advanced liver fibrosis. It is a once-daily oral tablet and the first drug of its kind approved by the FDA for this condition, which received approval in March 2024.
Where is Madrigal Pharmaceuticals headquartered, and how large is the company?
Madrigal Pharmaceuticals is headquartered in Conshohocken, PA, and has approximately 1,074 employees. If you need to find a specific contact there, a tool like Clay can help you locate verified email addresses using the company's firstinitiallast format.
Who leads Madrigal Pharmaceuticals as its chief executive?
Bill Sibold serves as President and Chief Executive Officer of Madrigal Pharmaceuticals. Other senior leaders include Mardi C. Dier as Executive Vice President and Chief Financial Officer, and Mark Underwood as Executive Vice President of Business Planning and Operations.
Has Madrigal Pharmaceuticals received approval for Rezdiffra outside the United States?
Yes, the European Commission granted approval for Rezdiffra (resmetirom) in August 2025 for the treatment of MASH with moderate to advanced liver fibrosis in adults, expanding Madrigal Pharmaceuticals' reach beyond the US market.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating